Por: Time Health March 18, 2023
Sanofi will cut the U.S. list price of two of its insulins, making it the third major producer of the diabetes medicine to recently slash prices. French pharmaceutical maker Sanofi will reduce the U.S. list price of Lantus, its most-prescribed insulin, by 78%, according to a Thursday. The company will also reduce the list price of Apidra by 70%. “We are pleased to see others join our efforts to help patients as we now accelerate the... + full article
Forbes USA Business March 17, 2023
Topline Pharmaceutical giant Sanofi announced Thursday it will cut the price of its most commonly prescribed insulin by 78% and cap the monthly cost at $35, becoming the latest drug maker—behind Eli Lilly and Novo Nordisk—to slash insulin costs this month, amid growing calls... + más
Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli Lilly | Forbes
How the Other Insulin Makers Are Responding to Eli Lilly’s Price Cap | Time
ABC7 USA Health March 17, 2023
Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday. The change is effective January 1.The move follows similar ones by Eli Lilly and... + más
Sanofi is the latest insulin maker to announce price cap | WPTV
Sanofi Cuts Insulin Prices Up To 78%—Following Eli Lilly And Novo Nordisk | Forbes
WPTV USA Nation March 17, 2023
Amid pressure from both the public and the Biden administration, a third insulin maker announced it is capping insulin prices. The announcement this week by Sanofi means the three largest insulin producers in the world have instituted price caps in recent... + más
Sanofi to cut U.S. insulin prices by up to 78%, capping cost at $35 | ABC7
Fox Business USA Business March 02, 2023
Arkansas Attorney General Leslie Rutledge provides insight into the conditions at the southern border as Title 42 is set to end and suing major pharma companies over raising the price of insulin. Eli Lilly is capping out-of-pocket costs for its insulin at $35 for patients,... + más
Eli Lilly To Lower Insulin Prices And Introduce A $35 Out-Of-Pocket Monthly Cap For Commercially Insured And Uninsured Diabetics | Forbes
Drugmaker Eli Lilly caps the cost of insulin at $35 a month, bringing relief for millions | NBC News
NBC News USA Nation March 01, 2023
Eli Lilly will cap the out-of-pocket cost of its insulin at $35 a month, the drugmaker said Wednesday. The move, experts say, could prompt other insulin makers in the U.S. to follow suit. The change, which Eli Lilly said takes effect immediately, puts the drugmaker in line with... + más
Eli Lilly plans to slash some insulin prices, expand cost cap | Orlando Sentinel
Eli Lilly plans to slash some insulin prices, expand cost cap | Portland Press Herald
ABC7 USA Health January 13, 2023
People are losing their lives because they can't afford the drug, Bonta said.Daphne Dorsey, associate director for media relations for Eli Lilly, said the company is disappointed by the California Attorney General's false accusations. She said the average... + más
California Joins Other States in Suing Companies Over Insulin Prices | The New York Times
More than 1 million Americans ration their insulin as the drug's cost skyrockets | CBS News
CBS News USA Health October 18, 2022
About 1.3 million Americans rationed their prescribed doses of insulin last year to save money, a pattern one doctor said threatens the health — and even the lives — of people with diabetes. Many people are taking less than the recommended amount of insulin as the cost of... + más
3 in 10 uninsured Americans with diabetes may ration insulin: Study | ABC News
1.3 million Americans with diabetes rationed insulin in the past year, study finds | CNN
About iurex | Privacy Policy | Disclaimer |